Company: SWKH
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001628280-25-025955
Chunk: 75

Company: SWK Holdings Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 8
Chunk 75
---
 profit (loss) to evaluate segment performance because the Company believes this measure is indicative of performance trends and the overall earnings potential of each segment. The Company does not report assets by reportable segment, as this metric is not used by the Company's CEO in assessing performance or allocating resources to the segments.

21

The following tables present financial information for the Company's reportable segments for the periods indicated (in thousands):Three Months Ended March 31, 2025Finance ReceivablesPharmaceutical Development and OtherHolding Company and OtherConsolidatedRevenue$10,712 $963 $— $11,675 Other revenue110 47 — 157 Benefit from credit losses(1,465)— — (1,465)Interest expense232 2 896 1,130 Pharmaceutical manufacturing, research and development expense— 758 — 758 Depreciation and amortization expense— — 19 19 General and administrative expense55 704 2,518 3,277 Other expense, net(2,214)(82)— (2,296)Income tax expense— — 1,278 1,278 Net income (loss)9,786 (536)(4,711)4,539 Three Months Ended March 31, 2024Finance ReceivablesPharmaceutical Development and OtherHolding Company and OtherConsolidatedRevenue$11,035 $279 $— $11,314 Other revenue46 — — 46 Provision for credit losses5,297 — — 5,297 Interest expense1,256 — — 1,256 Pharmaceutical manufacturing, research and development expense— 530 — 530 Depreciation and amortization expense— 492 22 514 General and administrative expense78 710 1,896 2,684 Other expense, net(382)— — (382)Income tax benefit— — 229 229 Net income (loss)4,068 (1,453)(2,147)468 The following table presents total assets for the Company's reportable segments for the periods indicated (in thousands):March 31, 2025December 31, 2024Total AssetsFinance receivables$297,961 $299,248 Pharmaceutical development and other9,013 7,786 Hold